An Unexpected Interaction between SofosbuvirLedipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function

Abstract EN

Hepatitis C virus (HCV) infection affects roughly 170 million people worldwide.

Sofosbuvir/Ledipasvir (Sof/Led) is a new once daily direct acting antiviral combination pill that was approved in October 2014 for use in patients with HCV genotype 1 infection.

Coadministration of Sof/Led is studied only with rosuvastatin which shows significantly increased level of drug and is associated with increased risk of myopathy, including rhabdomyolysis.

There is no mention of such HMG-CoA reductase inhibitor interaction as a class, as pravastatin did not have any clinically significant interaction with Sof/Led.

Other myotoxic drugs, including colchicine are not studied.

We present a case of a serious drug interaction between Sof/Led and atorvastatin, in the background of CKD and colchicine use.